Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21252140.
- Also identified by DOI 10.1093/cid/ciq196 and PMC identifier 3060905.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.
Medical subject headings
- Anti-HIV Agents
- Benzoxazines
- HIV
- HIV Infections
- Viral Load
- Viremia